Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gimeracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gimeracil SCHEMBL30536932 | 0.97 | HSD17B10 (0.42) | — | |
| Gimeracil SCHEMBL29073371 | 0.97 | HSD17B10 (0.42) | — | |
| SCHEMBL911633 | 0.81 | — | — | |
| SCHEMBL1425056 | 0.79 | — | — | |
| SCHEMBL30014014 | 0.79 | — | — | |
| SCHEMBL28307383 | 0.77 | HPGD (0.33) | — | |
| SCHEMBL16033479 | 0.75 | — | — | |
| SCHEMBL7902960 | 0.75 | — | — | |
| SCHEMBL20532547 | 0.75 | — | — | |
| SCHEMBL26287511 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172960-A1 | TOPICAL CAPECITABINE FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-06-08 | — | — | US | claimed |
| US-11559541-B2 | Topical capecitabine for the treatment of hyperproliferative skin conditions | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-01-24 | — | — | US | claimed |
| US-20210052620-A1 | TOPICAL CAPECITABINE FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2021-02-25 | — | — | US | claimed |
| CN-112245548-A | Medicine for treating gastric cancer by combining traditional Chinese medicine and western medicine | 梅钊 | 2021-01-22 | — | — | CN | claimed |
| EP-3752139-A1 | TOPICAL CAPECITABINE FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS | Taro Pharmaceutical Industries Ltd. (IL) | 2020-12-23 | — | — | EP | claimed |
| WO-2019144032-A1 | TOPICAL CAPECITABINE FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS | TARO PAHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-07-25 | — | — | WO | claimed |
| US-10086010-B2 | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | STC.UNM (US) | 2018-10-02 | — | — | US | claimed |
| US-20180125875-A1 | SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2018-05-10 | — | — | US | claimed |
| US-9877966-B1 | Combination therapy for the inhibition of metastasis and tumorigenesis | OLIVA EUGENE J (US) | 2018-01-30 | — | — | US | claimed |
| WO-2015142867-A1 | SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS | STC.UNM (US) | 2015-09-24 | — | — | WO | claimed |
| EP-1842847-A1 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-10 | — | — | EP | claimed |
| EP-1750703-A1 | METHOD FOR REDUCING GASTROINTESTINAL TOXICITY DUE TO THE ADMINISTRATION OF TEGAFUR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-14 | — | — | EP | claimed |
| EP-1677800-A1 | METHODS, COMPOSITIONS, AND KITS FOR ORGAN PROTECTION DURING SYSTEMIC ANTICANCER THERAPY | Ford, John P. (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050272689-A1 | Topical or injection administering fluoropyrimidine drug along with anticancer agent | ASYMMETRIC THERAPEUTICS, LLC | 2005-12-08 | — | — | US | claimed |
| WO-2005105086-A1 | METHOD FOR REDUCING GASTROINTESTINAL TOXICITY DUE TO THE ADMINISTRATION OF TEGAFUR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | claimed |
| US-20050118600-A1 | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | US | claimed |
| WO-2005039585-A1 | METHODS, COMPOSITIONS, AND KITS FOR ORGAN PROTECTION DURING SYSTEMIC ANTICANCER THERAPY | FORD JOHN P (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050059573-A1 | Methods, compositions, and kits for organ protection during systemic anticancer therapy | ASYMMETRIC THERAPEUTICS, LLC | 2005-03-17 | — | — | US | claimed |
| EP-0543015-B1 | COMPOSITION, METHOD AND KIT FOR POTENTIATING ANTITUMOR ACTIVITY AND FOR CURING TUMOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 1998-11-11 | — | — | EP | claimed |
| US-5525603-A | MIXTURE OF 2,4-DIHYDROXYPYRIDINE COMPOUND AND OXONIC ACIDADMINISTERED WITH TEGAFUR; SIDE-EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-06-11 | — | — | US | claimed |